Biomedicine diagnosis
Innovative solutions
Enlightening Biomedicine
Improve early breast cancer diagnosis
IS OUR MISSION
MAMOREF
OUR TECHNOLOGYSupported by
Thank you
Previous
Next
Main Issues
Reasons why we do what we do and that lead us to our mission:
Improve early breast cancer diagnosis
HIGH INCIDENCE OF BREAST CANCER
TECHNOLOGICAL LIMITATIONS
Main Issues
Reasons why we do what we do and that lead us to our mission:
Improve early breast cancer diagnosis
HIGH INCIDENCE OF BREAST CANCER
TECHNOLOGICAL LIMITATIONS
Competitive Advantages
Metabolic information
Portable, no infrastructure required
High specificity
No specialized operator and autonomous
No ionizing radiation.
Suitable for all patients
Our team and partners make all this possible!
Competitive Advantages
Metabolic information
Portable, no infrastructure required
High specificity
No specialized operator and autonomous
No ionizing radiation
Suitable for all patients
THANKS TO
Our team and partners make all this possible!
Investors
Strategic Partners
Managing Team
Pamela Pardini, PhD / CEO
Nicolás Carbone, PhD / CTO
Board of Directors
Tejas Mazmudar
Oren Gershtein
Board of Directors
Tejas Mazmudar Oren Gershtein Pamela Pardini, PhD / CEO
Scientific Team
|
|
|
|
|
|
|
|
Scientific Team
Facts & Goals
-
2005
Foundation of Biomedical Optics Group
-
2011
Optical mammography device idea
-
2017
Prendete award
-
2018
IB50k Award
-
2020
Birth of Bionirs
-
2020
CITES investment
-
2021
First prototype
-
2021
IP - national phases
-
2022
First clinical trials
-
2022
2nd prototype
-
2023
New design - prototype 2.0
Facts & Goals
2023
New Design - Prototype 2.0
2005
Foundation of Biomedical Optics Group
2011
Optical mammography device idea
2017
Prendete award
2018
IB50k Award
2020
Birth of Bionirs
2020
CITES investment
2021
First prototype
2021
IP - national phases
2022
First clinical trials
Become a partner!
|
📰 Featured in the News! 📰 |
|
📰 Featured in the News! 📰 |
UNICEN Campus Universitario – Tandil, Buenos Aires, Argentina contacto@bionirs.com
Follow us!
bionirs